Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2019-08-06 Regulatory Filings
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mitsubishi UFJ Financial Group
Regulatory Filings
2019-08-06 English
ALVOTECH AND CIPLA GULF ENTER INTO A PARTNERSHIP FOR THE COMMERCIALIZATION OF KEY BIOSIMILAR IN SELECT EMERGING MARKETS.
Regulatory Filings
2019-07-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated 29 July 2019 announcing a partnership between Alvotech and Cipla Gulf for commercialization of a biosimilar drug. It contains no financial statements, regulatory filings, or detailed financial data. It is a corporate announcement about a strategic partnership and commercial collaboration, not a financial report, regulatory filing, or management discussion. It does not fit categories like Annual Report, Earnings Release, or Capital Update. It is a general corporate announcement about a business partnership, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2019-07-29 English
Cipla USA furthers AMR stewardship with acquisition of key anti-infective ZEMDRI™ (IV Plazomicin).
Regulatory Filings
2019-07-24 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated July 24, 2019, announcing Cipla USA's acquisition of the anti-infective drug ZEMDRI (IV Plazomicin). It details the acquisition, product information, company background, and strategic implications. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about a capital transaction (acquisition of product rights) and business update rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a call transcript or AGM material. The content focuses on a financing-related acquisition and business update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a confident classification.
2019-07-24 English
Shareholders meeting
Regulatory Filings
2019-07-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.